Physician profile
Alejandro Mora
NPI 1992123673
$3,542.71
in general payments reported to CMS, 2019-2025
26 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $54.49 · 2021: $743 · 2022: $689 · 2023: $360 · 2024: $141 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Swiss Dental Solutions INC. | $1,216.91 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $412.19 | 2020-2024 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $398.90 | 2020-2022 | |
| Merz North America, INC. | $229.98 | 2022 | |
| Medtronic, INC. | $185.13 | 2025 | Venaseal, Nuvent |
| Novo Nordisk INC | $168.78 | 2022-2024 | Rybelsus, Wegovy, Ozempic |
| Lilly USA, LLC | $156.38 | 2021-2023 | Mounjaro, Jardiance |
| Gilead Sciences, INC. | $121.93 | 2022-2025 | |
| Glaxosmithkline, LLC. | $83.39 | 2020-2021 | |
| Viiv Healthcare Company | $78.38 | 2022-2024 | Apretude |
| Abbvie INC. | $69.39 | 2022-2024 | |
| Abbott Laboratories | $57.36 | 2021-2022 | |
| Edwards Lifesciences Corporation | $54.27 | 2022 | |
| Pfizer INC. | $43.73 | 2024-2025 | |
| Bridgebio Pharma, INC. | $38.09 | 2025 | Attruby |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $30.79 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.51 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $25.37 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $25.19 | 2025 | Trintellix |
| Linus Health, INC. | $20.04 | 2022 | |
| Merz Pharmaceuticals, LLC | $18.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.42 | 2022 | |
| Esperion Therapeutics, INC. | $18.35 | 2025 | Nexletol |
| Agile Therapeutics, INC. | $17.91 | 2023 | Twirla |
| Exact Sciences Corporation | $15.43 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Mora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.